Antiresorptive therapy for the prevention of postmenopausal osteoporosis: When should treatment begin?

Treatments in Endocrinology

Volumn 4, Issue 5, 2005, Pages 263-277

  Vestergaard, Peter ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM; ETIDRONIC ACID; RALOXIFENE; VITAMIN D; BONE DENSITY CONSERVATION AGENT;

BONE DENSITY; BONE TURNOVER; CORTICOSTEROID THERAPY; COST EFFECTIVENESS ANALYSIS; DUAL ENERGY X RAY ABSORPTIOMETRY; HORMONE SUBSTITUTION; HUMAN; MENOPAUSE; OSTEOLYSIS; OSTEOPOROSIS; POSTMENOPAUSE OSTEOPOROSIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SCREENING; DRUG EFFECT; FEMALE; METABOLISM; METHODOLOGY; TIME;

BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; OSTEOPOROSIS, POSTMENOPAUSAL; TIME FACTORS;

EID: 31144462288     PISSN: 11756349     EISSN: 11756349     Source Type: Journal    
DOI: 10.2165/00024677-200504050-00001     Document Type: Review

References (135)

1. Consensus Development Conference. Diagnosis, prophylaxis, and treatment of osteoporosis. Am J Med 1993; 94: 646-50
2. Alexeeva L, Burkhardt P, Christiansen C, et al. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: report of a WHO Study Group [WHO technical report series no. 843]. Geneva, WHO: 1994
3. Kanis JA. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. Osteoporos Int 1994; 4: 368-81
4. NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy. Osteoporosis prevention, diagnosis, and therapy. JAMA 2001; 285: 785-95
5. Faulkner KG, Orwoll E. Implications in the use of T-scores for the diagnosis of osteoporosis in men. J Clin Densitom 2002; 5: 87-93
6. Vestergaard P, Rejnmark L, Mosekilde L. Osteoporosis is markedly underdiagnosed: a nationwide study from Denmark. Osteoporos Int 2005; 16: 134-41
7. Kelly TJ. Bone mineral density reference database for American men and women [abstract]. J Bone Miner Res 1990; 5 Suppl. 2: S249
8. Kanis JA, Borgstrom F, De Laet C, et al. Assessment of fracture risk. Osteoporos Int 2005; 16: 581-9
9. Dorland's Illustrated Medical Dictionary. Philadelphia (PA): WB Saunders Co., 1985
10. Greendale GA, Lee NP, Arriola ER. The menopause. Lancet 1999; 353: 571-80
11. Boldsen JL, Jeune B. Distribution of age at menopause in two Danish samples. Hum Biol 1990; 62: 291-300
12. Flint M. Is there a secular trend in age of menopause? Maturitas 1978; 1: 133-9
13. Dawson-Hughes B, Gold DT, Rodbard HW, et al. Physician's guide to prevention and treatment of osteoporosis. Washington (DC): National Osteoporosis Foundation, 2003
14. Mundy GR, Chen D, Oyajobi BO. Bone remodeling. In: Favus MJ, editor. Primer on the metabolic bone diseases and disorders of bone metabolism. Washington (DC): ASBMR, 2003: 46-58
15. Eriksen EF, Vesterby A, Kassem M, et al. Bone remodeling and bone structure. In: Mundy GR, Martin TJ, editors. Physiology and pharmacology of bone. Berlin: Springer Verlag, 1993: 67-109
16. Vestergaard P, Mosekilde L, Brixen K. Antiresorptive therapy in osteoporosis. Ugeskr Laeger 2005; 167: 883-7
17. Blake GM, Wahner HW, Fogelman I. The evaluation of osteoporosis: dual energy x-ray absorptiometry and ultrasound in clinical practice. London: Martin Dunitz, 1999
18. Leib ES, Lewiecki EM, Brinkley N, et al. Official positions of the International Society for Clinical Densitometry. J Clin Densitom 2004; 7: 1-6
19. Riggs BL, Melton III LJ. Evidence for two distinct syndromes of involutional osteoporosis. Am J Med 1983; 75: 899-901
20. Vestergaard P, Krogh K, Rejnmark L, et al. Fracture rates and risk factors for fractures in patients with spinal cord injury. Spinal Cord 1998; 36: 790-6
21. Black DM, Cummings SR, Kerpf DB, et al. Randomised trial of the effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 1996; 348: 1535-41
22. Roy DK, O'Neill TW, Finn JD, et al. Determinants of incident vertebral fracture in men and women: results from the European Prospective Osteoporosis Study (EPOS). Osteoporos Int 2003; 14: 19-26
23. Rea JA, Chen MB, Li J, et al. Morphometric x-ray absorptiometry and morphometric radiography of the spine: a comparison of prevalent vertebral deformity identification. J Bone Miner Res 2000; 15: 564-74
24. Greenspan SL, von Stetten E, Emond SK, et al. Instant vertebral assessment: a noninvasive dual x-ray absorptiometry technique to avoid misclassification and clinical mismanagement of osteoporosis. J Clin Densitom 2001; 4: 373-80
25. Watts NB, Josse RG, Hamdy RC, et al. Risedronate prevents new vertebral fractures in postmenopausal women at high risk. J Clin Endocrinol Metab 2003; 88: 542-9
26. Vestergaard P, Mosekilde L. Fracture risk associated with smoking: a meta-analysis. J Intern Med 2003; 254: 572-83
27. Vestergaard P, Mosekilde L. Hyperthyroidism, bone mineral, and fracture risk: a meta-analysis. Thyroid 2003; 13: 585-93
28. Klotzbuecher CM, Ross PD, Landsman PB, et al. Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res 2000; 15: 721-39
29. Kanis JA, Johansson H, Oden A, et al. A family history of fracture and fracture risk: a meta-analysis. Bone 2004; 35: 1029-37
30. Vestergaard P, Rejnmark L, Mosekilde L. Fracture risk associated with systemic and topical corticosteroids. J Intern Med 2005; 257: 374-84
31. Vestergaard P. Fracture risk secondary to disease [thesis]. Aarhus: Faellestrykkeriet for Sundhedsvidenskab, 2003
32. Stein E, Shane E. Secondary osteoporosis. Endocrinol Metab Clin North Am 2003; 32: 115-34
33. van Staa TP, Abenhaim L, Cooper C, et al. Public health impact of adverse bone effects of oral corticosteroids. Br J Clin Pharmacol 2001; 51: 601-7
34. Prevention and management of osteoporosis. WHO technical report series no. 921. Geneva: WHO, 2003
35. Wilson JNG, Jungner F. Principles and practice of screening for disease [public health papers no. 34]. Geneva: WHO, 1968
36. Ray NF, Chan JK, Thamer M, et al. Medical expenditures for the treatment of osteoporotic fractures in the United States in 1995: report from the National Osteoporosis Foundation. J Bone Miner Res 1997; 12: 24-35
37. Cranney A, Guyatt G, Krolicki N, et al. A meta-analysis of etidronate for the treatment of postmenopausal osteoporosis. Osteoporos Int 2001; 12: 140-51
38. Cranney A, Tugwell P, Wells G, et al. Meta-analyses of therapies for postmenopausal osteoporosis. Endocr Rev 2002; 23: 496-507
39. Cranney A, Wells G, Willan A, et al. Meta-analysis of alendronate for the treatment of postmenopausal women. Endocr Rev 2002; 23: 508-16
40. Cranney A, Tugwell P, Zytaruk N, et al. Meta-analysis of calcitonin for the treatment of postmenopausal osteoporosis. Endocr Rev 2002; 23: 540-51
41. Cranney A, Tugwell P, Zytaruk N, et al. Meta-analysis of raloxifene for the prevention and treatment of postmenopausal osteoporosis. Endocr Rev 2002; 23: 524-8
42. Cranney A, Tugwell P, Adachi J, et al. Meta-analysis of risedronate for the treatment of postmenopausal osteoporosis. Endocr Rev 2002; 23: 517-23
43. Cranney A, Guyatt G, Griffith L, et al. Summary of meta-analyses of therapies for postmenopausal osteoporosis. Endocr Rev 2002; 23: 570-8
44. Papadimitropoulos E, Wells G, Shea B, et al. Meta-analysis of the efficacy of vitamin D treatment in preventing osteoporosis in postmenopausal women. Endocr Rev 2002; 23: 560-9
45. Shea B, Wells G, Cranney A, et al. Meta-analysis of calcium supplementation for the prevention of postmenopausal osteoporosis. Endocr Rev 2002; 23: 552-9
46. Wells G, Tugwell P, Shea B, et al. Meta-analysis of the efficacy of hormone replacement therapy in treating and preventing osteoporosis in postmenopausal women. Endocr Rev 2002; 23: 529-39
47. Osteoporosis in the European Community. Action plan (a report of the European Osteoporosis Consultation Panel, IOF-EC-Policy4, Nov 03). Brussels: European Community, 2003
48. Cheung AM, Feig DS, Kapral M, et al. Prevention of osteoporosis and osteoporotic fractures in postmenopausal women: recommendation statement from the Canadian Task Force on Preventive Health Care. CMAJ 2004; 170: 1665-7
49. Changes in the criteria for reimbursement of bisphosphonates or raloxifene for preventing osteoporosis [abstract]. Ugeskr Laeger 2000; 162: 6512
50. Fuleihan GE, Baddoura R, Awada H, et al. Practice guidelines on the use of bone mineral density measurements who to test? What measures to use? When to treat? A Consensus report from the Middle East Densitometry Workshop. Leb Med J 2002; 50: 89-104
51. Raef H, Frayha HH, El-Shaker M, et al. Recommendations for the diagnosis and management of osteoporosis: a local perspective. Ann Saudi Med 2004; 24: 242-52
52. North American Menopause Society. Management of postmenopausal osteoporosis: position statement of the North American Menopause Society. Menopause 2002; 9: 84-101
53. Jorgensen JT, Andersen PB, Rosholm A, et al. Digital x-ray radiogrammetry: a new appendicular bone densitometric method with high precision. Clin Physiol 2000; 20: 330-5
54. Garnero P, Sornay-Rendu E, Claustrat B, et al. Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women: the OFELY study. J Bone Miner Res 2000; 15: 1526-36
55. Vestergaard P, Hermann AP, Gram J, et al. Evaluation of methods for prediction of bone mineral density by clinical and biochemical variables in perimenopausal women. Maturitas 2001; 40: 211-20
56. Sen SS, Rives VP, Messina OD, et al. A risk assessment tool (OsteoRisk) for identifying Latin American women with osteoporosis. J Gen Intern Med 2005; 20: 245-50
57. Cadarette SM, Jaglal SB, Murray TM, et al. Evaluation of decision rules for referring women for bone densitometry by dual-energy x-ray absorptiometry. JAMA 2001; 286: 57-63
58. Black DM, Steinbuch M, Palermo L, et al. An assessment tool for predicting fracture risk in postmenopausal women. Osteoporos Int 2001; 12: 519-28
59. Wallace LS, Ballard JE, Holiday D, et al. Evaluation of decision rules for identifying low bone density in postmenopausal African-American women. J Natl Med Assoc 2004; 96: 290-6
60. Koh LK, Sedrine WB, Torralba TP, et al. A simple tool to identify Asian women at increased risk of osteoporosis. Osteoporos Int 2001; 12: 699-705
61. Geusens P, Hochberg MC, van der Voort DJ, et al. Performance of risk indices for identifying low bone density in postmenopausal women. Mayo Clin Proc 2002; 77: 629-37
62. Clinical practice guidelines for the diagnosis and management of osteoporosis: Scientific Advisory Board, Osteoporosis Society of Canada. CMAJ 1996; 155: 1113-33
63. Kanis JA, Torgerson D, Cooper C. Comparison of the European and USA practice guidelines for osteoporosis. Trends Endocrinol Metab 2000; 11: 28-32
64. Kleerekoper M. Treatment of osteoporosis. Clin Obstet Gynecol 2004; 47: 413-23
65. Compston JE, Papapoulos SE, Blanchard JF. Report on osteoporosis in the European community: current status and recommendations for the future. Osteoporos Int 1998; 8: 531-4
66. Eastell R, Reid DM, Compston J, et al. A UK consensus group on management of glucocorticoid-induced osteoporosis: an update. J Intern Med 1998; 244: 271-92
67. Eastell R, Reid DM, Compston J, et al. Secondary prevention of osteoporosis: when should a non-vertebral fracture be a trigger for action? QJM 2001; 94: 575-97
68. Genant HK, Cooper C, Poor G, et al. Interim report and recommendations of the World Health Organization Task-Force for Osteoporosis. Osteoporos Int 1999; 10: 259-64
69. Meunier PJ, Delmas PD, Eastell R, et al. Diagnosis and management of osteoporosis in postmenopausal women: clinical guidelines. International Committee for Osteoporosis Clinical Guidelines. Clin Ther 1999; 21: 1025-44
70. Morii H, Genant HK. Statement on the diagnosis and management of osteoporosis from the Consensus Development Conference at the Second International Conference on Osteoporosis, Osaka 1997. J Bone Miner Metab 1998; 16: 206-14
71. Reginster JY. Prevention of postmenopausal osteoporosis with pharmacological therapy: practice and possibilities. J Intern Med 2004; 255: 615-28
72. Vestergaard P, Rejnmark L, Mosekilde L. Hip fracture prevention: cost-effective strategies. Pharmacoeconomics 2001; 19: 449-68
73. Siris ES, Chen YT, Abbott TA, et al. Bone mineral density thresholds for pharmacological intervention to prevent fractures. Arch Intern Med 2004; 164: 1108-12
74. Marshall D, Johnell O, Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 1996; 312: 1254-9
75. Phillips S, Fox N, Jacobs J, et al. The direct medical costs of osteoporosis for American women aged 45 and older, 1986. Bone 1988; 9: 271-9
76. Lauritzen JB, Petersen MM, Lund B. Effect of external hip protectors on hip fractures. Lancet 1993; 341: 11-3
77. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002; 288: 321-33
78. Cauley JA, Robbins J, Chen Z, et al. Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial. JAMA 2003; 290: 1729-38
79. The Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004; 291: 1701-12
80. International Osteoporosis Foundation. Evidence-based guidelines currently available [online]. Available from URL: http://www.osteofound.org/ health_professionals/guidelines/guidelines_list.html [Accessed 2005 May 1]
81. Cummings SR, Nevitt MC, Browner WS, et al. Risk factors for hip fracture in white women: Study of Osteoporotic Fractures Research Group. N Engl J Med 1995; 332: 767-73
82. Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 1998; 280: 2077-82
83. Looker AC, Wahner HW, Dunn WL, et al. Updated data on proximal femur bone mineral levels of US adults. Osteoporosis Int 1999; 8: 468-89
84. Heaney RP, Zizic TM, Fogelman I, et al. Risedronate reduces the risk of first vertebral fracture in osteoporotic women. Osteoporos Int 2002; 13: 501-5
85. Delmas PD, Ensrud KE, Adachi JD, et al. Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial. J Clin Endocrinol Metab 2002; 87: 3609-17
86. McClung MR, Geusens P, Miller PD, et al. Effect of risedronate on the risk of hip fracture in elderly women: Hip Intervention Program Study Group. N Engl J Med 2001; 344: 333-40
87. Kanis JA, Johansson H, Oden A, et al. A meta-analysis of prior corticosteroid use and fracture risk. J Bone Miner Res 2004; 19: 893-9
88. Kanis JA, Johnell O, De Laet C, et al. A meta-analysis of previous fracture and subsequent fracture risk. Bone 2004; 35: 375-82
89. Kanis JA, Johansson H, Johnell O, et al. Alcohol intake as a risk factor for fracture. Osteoporos Int 2005 Jul; 16 (7): 737-42
90. Kanis JA, Johansson H, Oden A, et al. A meta-analysis of milk intake and fracture risk: low utility for case finding. Osteoporos Int 2005 Jul; 16 (7): 799-804
91. Kanis JA, Johnell O, Oden A, et al. Smoking and fracture risk: a meta-analysis. Osteoporos Int 2005 Feb; 16 (2): 155-62
92. Chapuy MC, Arlot ME, Duboeuf F, et al. Vitamin D, and calcium to prevent hip fractures in elderly women. N Engl J Med 1992; 327: 1637-42
93. Chapuy MC, Arlot ME, Delmas PD, et al. Effect of calcium and cholecalciferol treatment for three years on hip fractures in elderly women. BMJ 1994; 308: 1081-2
94. Larsen ER, Mosekilde L, Foldspang A. Vitamin D and calcium supplementation prevents osteoporotic fractures in elderly community dwelling residents: a pragmatic population-based 3-year intervention study. J Bone Miner Res 2004; 19: 370-8
95. Trivedi TP, Doll R, Khaw KT. Effect of four monthly oral vitamin D3 (cholecalciferol) supplementation on fractures and mortality in men and women living in the community: randomised double-blind controlled trial. BMJ 2003; 326: 469-75
96. Heikinheimo RJ, Inkovaara JA, Harju EJ, et al. Annual injection of vitamin D and fractures of aged bones. Calcif Tissue Int 1992; 51: 105-10
97. Lips P, Graafmans WC, Ooms ME, et al. Vitamin D supplementation and fracture incidence in elderly persons. A randomized, placebo-controlled clinical trial. Ann Intern Med 1996; 124: 400-6
98. Meyer HE, Smedshaug GB, Kvaavik E, et al. Can vitamin D supplementation reduce the risk of fracture in the elderly? A randomized controlled trial. J Bone Miner Res 2002; 17: 709-15
99. Dawson-Hughes B, Harris SS, Krall EA, et al. Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. N Engl J Med 1997; 337: 670-6
100. Homik J, Suarez-Almazor ME, Shea B, et al. Calcium and vitamin D for corticosteroid-induced osteoporosis. Cochrane Database Syst Rev 2000; (2): CD000952
101. Vestergaard P, Mosekilde L. Economic cost of different intervention regimens to prevent hip fractures. Ugeskr Laeger 1999; 161: 4400-5
102. Torgerson DJ, Kanis JA. Cost-effectiveness of preventing hip fractures in the elderly population using vitamin D and calcium. QJM 1995; 88: 135-9
103. Grant AM, Avenell A, Campbell MK, et al. Oral vitamin D3 and calcium for secondary prevention of low-trauma fractures in elderly people (Randomised Evaluation of Calcium OR vitamin D, RECORD): a randomised placebo-controlled trial. Lancet 2005; 365: 1621-8
104. Porthouse J, Cockayne S, King C, et al. Randomised controlled trial of calcium and supplementation with cholecalciferol (vitamin D3) for prevention of fractures in primary care. BMJ 2005; 330: 1003-9
105. Effects of hormone therapy on bone mineral density: results from the postmenopausal estrogen/progestin interventions (PEPI) trial. JAMA 1996; 276: 1389-96
106. Mosekilde L, Beck-Nielsen H, Sorensen OH, et al. Hormonal replacement therapy reduces forearm fracture incidence in recent postmenopausal women: results of the Danish Osteoporosis Prevention Study. Maturitas 2000; 36: 181-93
107. EMEA. EMEA public statement on recent publications regarding hormone replacement therapy [online]. Available from URL: http://www.emea.eu.int/pdfs/ human/press/pus/3306503en.pdf [Accessed 2005 May 1]
108. Beral V, Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003; 362: 419-27
109. Beral V, Banks E, Reeves G. Evidence from randomised trials on the long-term effects of hormone replacement therapy. Lancet 2002; 360: 942-4
110. Brecht JG, Kruse HP, Mohrke W, et al. Health-economic comparison of three recommended drugs for the treatment of osteoporosis. Int J Clin Pharmacol Res 2004; 24: 1-10
111. Brumsen C, Papapoulos SE, Lips P, et al. Daily oral pamidronate in women and men with osteoporosis: a 3-year randomized placebo-controlled clinical trial with a 2-year open extension. J Bone Miner Res 2002; 17: 1057-64
112. Reid IR, Brown JP, Burckhardt P, et al. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med 2002; 346: 653-61
113. Ringe JD, Dorst A, Faber H, et al. Intermittent intravenous ibandronate injections reduce vertebral fracture risk in corticosteroid-induced osteoporosis: results from a long-term comparative study. Osteoporos Int 2003; 14: 801-7
114. Liberman UA, Weiss SR, Broll J, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis: the Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med 1995; 333: 1437-43
115. Pols HA, Felsenberg D, Hanley DA, et al. Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Foxamax International Trial Study Group. Osteoporos Int 1999; 9: 461-8
116. Adachi JD, Bensen WG, Brown J, et al. Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. N Engl J Med 1997; 337: 382-7
117. Adachi JD, Saag KG, Delmas PD, et al. Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial. Arthritis Rheum 2001; 44: 202-11
118. Geusens P, Dequeker J, Vanhoof J, et al. Cyclical etidronate increases bone density in the spine and hip of postmenopausal women receiving long term corticosteroid treatment: a double-blind, randomised placebo-controlled study. Ann Rheum Dis 1998; 57: 724-7
119. Jenkins EA, Walker-Bone KE, Wood A, et al. The prevention of corticosteroid-induced bone loss with intermittent cyclical etidronate. Scand J Rheumatol 1999; 28: 152-6
120. Reid DM, Hughes RA, Laan RF, et al. Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. European Corticosteroid-Induced Osteoporosis Treatment Study. J Bone Miner Res 2000; 15: 1006-13
121. Roux C, Oriente P, Laan R, et al. Randomised trial of effect of cyclical etidronate in the prevention of corticosteroid-induced bone loss: Ciblos Study Group. J Clin Endocrinol Metab 1998; 83: 1128-33
122. Saag KG, Emkey R, Schnitzer TJ, et al. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. N Engl J Med 1998; 339: 292-9
123. Sambrook PN, Kotowicz M, Nash P, et al. Prevention and treatment of glucocorticoid-induced osteoporosis: a comparison of calcitriol, vitamin D plus calcium, and alendronate plus calcium. J Bone Miner Res 2003; 18: 919-24
124. Wallach S, Cohen S, Reid DM, et al. Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy. Calcif Tissue Int 2000; 67: 277-85
125. Amin S, Lavalley MP, Simms RW, et al. The comparative efficacy of drug therapies used for the management of corticosteroid-induced osteoporosis: a meta-regression. J Bone Miner Res 2002; 17: 1512-26
126. Whyte MP, Wenkert D, Clements KL, et al. Bisphosphonate-induced osteopetrosis. N Engl J Med 2003; 349: 457-63
127. Jönsson L, Borgström F, Zethraeus N. Omkostningseffektivitet ved alendronatbehandling af osteoporose i Danmark. Ugeskr Laeger 2003; 165: 4112-6
128. Chesnut III CH, Silverman S, Andriano KA, et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the Prevent Recurrence of Osteoporotic Fractures study. PROOF Study Group. Am J Med 2000; 109: 267-76
129. Cranney A, Welch V, Adachi JD, et al. Calcitonin for the treatment and prevention of corticosteroid-induced osteoporosis. Cochrane Database Syst Rev 2000; (2): CD001983
130. Vestergaard P, Hermann AP, Gram J, et al. Improving compliance with hormonal replacement therapy in primary osteoporosis prevention. Maturitas 1997; 28: 137-45
131. Christensen PM, Brixen K, Gyrd-Hansen D, et al. Cost-effectiveness of alendronate in the prevention of osteoporotic fractures in Danish women. Basic Clin Pharmacol Toxicol 2005; 96: 387-96
132. Delmas PD. The use of bisphosphonates in the treatment of osteoporosis. Curr Opin Rheumatol 2005; 17: 462-6
133. Segal E, Tamir A, Ish-Shalom S. Compliance of osteoporotic patients with different treatment regimens. Isr Med Assoc J 2003; 5: 859-62
134. Brown JP, Josse RG. 2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. CMAJ 2002; 167: S1-34
135. Adler RA, Hochberg MC. Suggested guidelines for evaluation and treatment of glucocorticoid-induced osteoporosis for the Department of Veterans Affairs. Arch Intern Med 2003; 163: 2619-24